Study Design and Baseline Characteristics in Phase 2 Studies of Elezanumab, a Potential Neurorestorative Therapy for Multiple Sclerosis

Authors
Category Primary study
JournalNeurology
Year 2021
This article has no abstract
Epistemonikos ID: 405908270b5642014e7905af4d216a96431a9b29
First added on: Feb 13, 2025